AccuStem Sciences, Inc. Stock

Equities

ACUT

US00444A1016

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets 01:25:18 2024-06-03 pm EDT 5-day change 1st Jan Change
0.35 USD -25.52% Intraday chart for AccuStem Sciences, Inc. +26.35% -44.06%
Sales 2022 - Sales 2023 - Capitalization 7.1M
Net income 2022 -3M Net income 2023 -2M EV / Sales 2022 -
Net cash position 2022 627K Net Debt 2023 34.2K EV / Sales 2023 -
P/E ratio 2022
-3.97 x
P/E ratio 2023
-3.46 x
Employees 3
Yield 2022 *
-
Yield 2023
-
Free-Float 54.34%
More Fundamentals * Assessed data
Dynamic Chart
AccuStem Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
AccuStem Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
AccuStem Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
AccuStem Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
AccuStem Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Accustem Sciences, Inc. and Emeritusdx Announce Joint Product Development Agreement and Strategic Partnership CI
Accustem Sciences Inc. Announces Resignation of Jeff Fensterer as Chief Operating Officer, Effective as of June 16, 2023 CI
AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals CI
Accustem Sciences Inc. Announces Strategic Clinical and Operational Partnership CI
Accustem Sciences Inc. Appoints Sean McDonald to Its Board of Directors CI
Accustem Sciences Inc. Appoints Wendy Blosser as Director to Serve on the Board CI
Accustem Sciences Inc. announced that it expects to receive $2.67594 million in funding CI
AccuStem to Build Corporate Headquarters in Phoenix, Arizona CI
AccuStem Sciences, Inc. Appoints New Executive Leadership Team CI
AccuStem Sciences, Inc. Appoints Wendy Blosser as Chief Executive Officer CI
More news
1 day-25.52%
1 week+26.35%
Current month-25.52%
1 month-9.79%
3 months-22.41%
6 months-48.20%
Current year-44.06%
More quotes
1 week
0.30
Extreme 0.303
0.48
1 month
0.28
Extreme 0.277
0.48
Current year
0.27
Extreme 0.2707
0.72
1 year
0.27
Extreme 0.2707
1.95
3 years
0.26
Extreme 0.261
3.00
5 years
0.26
Extreme 0.261
3.00
10 years
0.26
Extreme 0.261
3.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 22-03-03
Director of Finance/CFO 47 21-07-31
Corporate Officer/Principal 49 22-03-03
Members of the board TitleAgeSince
Director/Board Member 76 21-02-28
Director/Board Member 72 21-02-28
Founder 52 20-06-04
More insiders
Date Price Change Volume
24-06-03 0.35 -25.52% 736
24-05-31 0.4699 -0.02% 2,031

Delayed Quote OTC Markets, June 03, 2024 at 01:25 pm EDT

More quotes
AccuStem Sciences, Inc. is a clinical-stage diagnostics company. The Company is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. The Company's product candidate is StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. In addition, the Company is focused on offering ancillary commodity testing (hereditary genetic testing, somatic mutation testing) that augments its assays and provides additional information to patients and physicians throughout the patient care continuum. The Company also holds licensing rights for the MicroRNA Signature Classifier (MSC) test, which is designed to help determine whether lung nodules identified by low-dose computed tomography (LDCT) screening are benign or malignant. The Company's wholly owned subsidiary is StemPrintER Sciences Limited.
More about the company